MedTrace Logo

Role of ROS and cAMP-PKA Biomarkers in ADPKD

NCT07217158 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-10-27

No results posted yet for this study

Summary

The primary objective is to determine the prognostic value of markers of ROS and cAMP-PKA signaling to assess disease severity and progression in patients with ADPKD.

Conditions

  • Autosomal Dominant Polycystic Kidney Disease

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Maria V. Irazabal, M.D., Ph.D. · Mayo Clinic

Eligibility

Min Age
15 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2027-03-31
Completion
2027-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07217158 on ClinicalTrials.gov